John Youssef, MD
Pulmonary Disease · Flint, MINPI 1467595975
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (38.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Intuitive Surgical at 51.4% of the total. Reporting peaked in 2024 at $6,381 and has fallen 81.2% since, to $1,201 in 2025.
Across 111 payments — averaging $97.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$237
- Amgen$182
- Insmed, Inc.$181
- plus $1K from 22 others
Across 15 payments — averaging $5393.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$71K
- AstraZeneca$9K
What the payments were for
- Consulting fees$1,35012%
- Travel & lodging$1,56014%
- Food & beverage$3,72734%
- Education$4,17239%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $5,560 |
| AstraZeneca | 15 | $1,916 |
| GSK | 26 | $1,265 |
| Regeneron Healthcare Solutions, Inc. | 8 | $237 |
| Amgen | 11 | $182 |
| Insmed, Inc. | 8 | $181 |
| Johnson & Johnson | 1 | $146 |
| Gilead | 2 | $136 |
| Abiomed | 1 | $134 |
| Baxter Healthcare | 4 | $114 |
| La Jolla Pharmaceutical Company | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 1 | $100 |
| Paratek Pharmaceuticals, Inc. | 1 | $95 |
| Medtronic | 1 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Sanofi | 2 | $58 |
| Genentech USA, Inc. | 1 | $55 |
| Verona Pharma, Inc. | 2 | $53 |
| Boehringer Ingelheim | 2 | $46 |
| Pulmonx Corporation | 1 | $37 |
| Novartis | 1 | $30 |
| Pharming Healthcare, Inc. | 1 | $30 |
| Mylan Specialty L.p. | 2 | $29 |
| United Therapeutics Corporation | 1 | $25 |
| Inogen, Inc. | 1 | $23 |
| AbbVie | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,491
- AIRSUPRA$1,350
- BREZTRI$361
- AREXVY$352
- NUCALA$239
- Monarch Platform$146
- Impella$134
- Veklury$125
How this compares
$10,810 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 486 | $520,061 |
| Spiriva RespimatTiotropium Bromide | 218 | $186,885 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $132,348 |
| Breo ElliptaFluticasone/Vilanterol | 143 | $81,791 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 164 | $70,648 |
| Pirfenidone | 18 | $60,605 |
| Advair HfaFluticasone Propion/Salmeterol | 97 | $55,849 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $52,451 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $37,528 |
| Incruse ElliptaUmeclidinium Bromide | 92 | $36,131 |
| SymbicortBudesonide/Formoterol Fumarate | 106 | $31,585 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 718 | $26,060 |
| Qvar RedihalerBeclomethasone Dipropionate | 59 | $25,586 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $24,926 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $24,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,265 | $671,285783 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $46 | $248,506289 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $1,916 | $89,427192 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Flint
- Arshia VahabzadehFlint$22K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.